Gastric Cancer Complicated With Bleeding
Not yet recruiting
- Conditions
- Gastric Cancer
- Interventions
- Drug: systematic therapy
- Registration Number
- NCT06522542
- Lead Sponsor
- Peking University Third Hospital
- Brief Summary
To investigate the impact of bleeding on the survival and treatment-related adverse events (TRAEs) of gastric cancer patients.
- Detailed Description
We will retrospectively enroll patients diagnosed with advanced or metastatic gastric cancer at the Department of Medical Oncology and Radiation Sickness of Peking University Third Hospital. The retrospective study aims to investigate the impact of bleeding on treatment-related adverse events (TRAEs) for gastric cancer patients receiving systematic anticancer treatment, assess the influence of bleeding on the survival of patients.
Recruitment & Eligibility
- Status
- NOT_YET_RECRUITING
- Sex
- All
- Target Recruitment
- 200
Inclusion Criteria
- Patients older than 18 years;
- A histologically confirmed diagnosis of advanced or metastatic gastric cancer;
- The initial anticancer treatment was systematic therapy, including chemotherapy, targeted therapy or immune checkpoint inhibitor (ICI);
- No history of gastrectomy before systematic therapy.
Read More
Exclusion Criteria
- Incompletable clinical data;
- Siewert I type esophagus cancer.
Read More
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description Test group systematic therapy Gastirc cancer with bleeding at first diagnosis Control group systematic therapy Gastirc cancer without bleeding at first diagnosis
- Primary Outcome Measures
Name Time Method Overall survival (OS) from date of the first cycle of systematic therapy to death from any cause，assessed up to 120 months OS was defined as the time from the first cycle of systematic therapy to death from any cause.
- Secondary Outcome Measures
Name Time Method